[
  {
    "ts": "2025-10-14T17:33:00+00:00",
    "headline": "Top Novavax Shareholder Demands Company’s Sale",
    "summary": "Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself.",
    "url": "https://www.barrons.com/articles/top-novavax-shareholder-demands-company-sale-5ca17c26?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "cbc1433d-4cfd-3cae-a724-2d45b38e4b18",
      "content": {
        "id": "cbc1433d-4cfd-3cae-a724-2d45b38e4b18",
        "contentType": "STORY",
        "title": "Top Novavax Shareholder Demands Company’s Sale",
        "description": "",
        "summary": "Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should sell itself.",
        "pubDate": "2025-10-14T17:33:00Z",
        "displayTime": "2025-10-14T17:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cbc1433d-4cfd-3cae-a724-2d45b38e4b18/top-novavax-shareholder.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a578fe3552e89b3a0a85326a0dade39e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OBtCSKJSbId2rIBE9uwCmA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a578fe3552e89b3a0a85326a0dade39e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E_0shnDr0la7f3Bb24Ne6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a578fe3552e89b3a0a85326a0dade39e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/top-novavax-shareholder-demands-company-sale-5ca17c26?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T14:57:00+00:00",
    "headline": "5 Small Drug Stocks to Buy as the Industry Shows Some Recovery",
    "summary": "Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.",
    "url": "https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2f7a56e3-5174-3bab-bae9-e976afc061e1",
      "content": {
        "id": "2f7a56e3-5174-3bab-bae9-e976afc061e1",
        "contentType": "STORY",
        "title": "5 Small Drug Stocks to Buy as the Industry Shows Some Recovery",
        "description": "",
        "summary": "Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.",
        "pubDate": "2025-10-14T14:57:00Z",
        "displayTime": "2025-10-14T14:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kOx_hEoutoKbvEBeeXdzsA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9I2cfbMe3krq0DVrblX.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-small-drug-stocks-buy-145700720.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T14:38:00+00:00",
    "headline": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?",
    "summary": "CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.",
    "url": "https://finance.yahoo.com/news/cormedix-stock-plunges-16-month-143800622.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "81f63871-7a29-3da0-90ac-fb6af2adc45e",
      "content": {
        "id": "81f63871-7a29-3da0-90ac-fb6af2adc45e",
        "contentType": "STORY",
        "title": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?",
        "description": "",
        "summary": "CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.",
        "pubDate": "2025-10-14T14:38:00Z",
        "displayTime": "2025-10-14T14:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.5Q_kyoqtcpsM1l1uvN2bQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KBUfPU_diptiGFZTYziQbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9ba18c9e2c8fffeabdd247f567de5466.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cormedix-stock-plunges-16-month-143800622.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cormedix-stock-plunges-16-month-143800622.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CRMD"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T14:01:00+00:00",
    "headline": "BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?",
    "summary": "Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment",
    "url": "https://finance.yahoo.com/news/bmy-slips-below-50-day-140100614.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "85b2605e-12b4-3c21-b5e4-ee1d54beaafd",
      "content": {
        "id": "85b2605e-12b4-3c21-b5e4-ee1d54beaafd",
        "contentType": "STORY",
        "title": "BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment",
        "pubDate": "2025-10-14T14:01:00Z",
        "displayTime": "2025-10-14T14:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-slips-below-50-day-140100614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-slips-below-50-day-140100614.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T12:43:00+00:00",
    "headline": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
    "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
    "url": "https://www.barrons.com/articles/johnson-johnson-earnings-jnj-stock-price-95523dd6?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "679a2f9a-5aca-3a2a-8bb6-3de1fb6df007",
      "content": {
        "id": "679a2f9a-5aca-3a2a-8bb6-3de1fb6df007",
        "contentType": "STORY",
        "title": "Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping.",
        "description": "",
        "summary": "Johnson & Johnson  reported better-than-expected earnings Tuesday, while announcing it would spin off a slower-growing division within its medical devices segment that makes hip and knee implants.  Now, Johnson & Johnson plans to separate that business into a new company that will operate under the name DePuy Synthes.  While sales for Johnson & Johnson’s medical devices division grew 5.6% on an operational basis between the third quarter of 2024 and the third quarter of 2025, orthopaedics sales grew more slowly, up just 2.4% over the same period.",
        "pubDate": "2025-10-14T12:43:00Z",
        "displayTime": "2025-10-14T12:43:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/679a2f9a-5aca-3a2a-8bb6-3de1fb6df007/johnson-johnson-earnings.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QzY9AKsRjKPpaqJUuHbirg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QfAW0SnRd723U8XuTnrzOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90d6196d555c709904771580a5fe7e34.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/johnson-johnson-earnings-jnj-stock-price-95523dd6?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T10:45:00+00:00",
    "headline": "TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial",
    "summary": "NEW YORK, October 14, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy",
    "url": "https://finance.yahoo.com/news/tukysa-combination-significantly-improves-progression-104500956.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c16c9e9b-2f0e-355a-bd4e-648c80aafced",
      "content": {
        "id": "c16c9e9b-2f0e-355a-bd4e-648c80aafced",
        "contentType": "STORY",
        "title": "TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial",
        "description": "",
        "summary": "NEW YORK, October 14, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy",
        "pubDate": "2025-10-14T10:45:00Z",
        "displayTime": "2025-10-14T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/bcd3202f83bf254b140a46249dc796fc",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WnFyV211r1TMhiyazrAjxg--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bcd3202f83bf254b140a46249dc796fc.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dHCGty31gMKCB1cb1ezIBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bcd3202f83bf254b140a46249dc796fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tukysa-combination-significantly-improves-progression-104500956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tukysa-combination-significantly-improves-progression-104500956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-14T03:16:51+00:00",
    "headline": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%. Pfizer Inc. (NYSE:PFE) is a‌ major US pharmaceutical and biotech‍n‍ology company that‌ offers a wide rang‌e⁠ o‌f products and services. In rec‌ent years, the company has experienced declini‍ng rev​e‌nue and profits, leading t⁠o a signific⁠an‍t d‌r⁠op in i‌ts‌ market value. […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-pipeline-dividend-yield-031651991.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d2988358-af7a-3b20-9687-caf5c66c8dd9",
      "content": {
        "id": "d2988358-af7a-3b20-9687-caf5c66c8dd9",
        "contentType": "STORY",
        "title": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is included among the 12 Best Dividend Stocks with Yields Above 4%. Pfizer Inc. (NYSE:PFE) is a‌ major US pharmaceutical and biotech‍n‍ology company that‌ offers a wide rang‌e⁠ o‌f products and services. In rec‌ent years, the company has experienced declini‍ng rev​e‌nue and profits, leading t⁠o a signific⁠an‍t d‌r⁠op in i‌ts‌ market value. […]",
        "pubDate": "2025-10-14T03:16:51Z",
        "displayTime": "2025-10-14T03:16:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-pipeline-dividend-yield-031651991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-pipeline-dividend-yield-031651991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]